NASDAQ:BCYC Bicycle Therapeutics (BCYC) Stock Price, News & Analysis → A Silent Invasion of America (From The Freeport Society) (Ad) Free BCYC Stock Alerts $23.25 -1.05 (-4.32%) (As of 03:24 PM ET) Add Compare Share Share Today's Range$23.14▼$24.1950-Day Range$21.36▼$24.6952-Week Range$12.54▼$28.91Volume103,891 shsAverage Volume366,681 shsMarket Capitalization$994.64 millionP/E RatioN/ADividend YieldN/APrice Target$46.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Bicycle Therapeutics alerts: Email Address Bicycle Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside101.0% Upside$46.86 Price TargetShort InterestHealthy6.12% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.49Based on 6 Articles This WeekInsider TradingSelling Shares$126,139 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.44) to ($5.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.23 out of 5 starsMedical Sector523rd out of 917 stocksPharmaceutical Preparations Industry243rd out of 431 stocks 3.4 Analyst's Opinion Consensus RatingBicycle Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBicycle Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Bicycle Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.12% of the outstanding shares of Bicycle Therapeutics have been sold short.Short Interest Ratio / Days to CoverBicycle Therapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Bicycle Therapeutics has recently decreased by 9.34%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBicycle Therapeutics does not currently pay a dividend.Dividend GrowthBicycle Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCYC. Previous Next 3.6 News and Social Media Coverage News SentimentBicycle Therapeutics has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Bicycle Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for BCYC on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows3 people have added Bicycle Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $126,139.00 in company stock.Percentage Held by InsidersOnly 8.50% of the stock of Bicycle Therapeutics is held by insiders.Percentage Held by Institutions86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bicycle Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($4.44) to ($5.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicycle Therapeutics is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicycle Therapeutics is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicycle Therapeutics has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Bicycle Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe Key to this $10 Trillion Tech BoomPresident Biden has just approved $2.6 billion for this breakthrough technology… And it has nothing to do with artificial intelligence, cryptocurrency, or the blockchain.To get all the details of this new tech – click here now. About Bicycle Therapeutics Stock (NASDAQ:BCYC)Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Read More BCYC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCYC Stock News HeadlinesJune 3, 2024 | businesswire.comBicycle Therapeutics to Participate in Upcoming Investor ConferencesMay 24, 2024 | seekingalpha.comBicycle Therapeutics Boosts Balance Sheet To Navigate Data DesertMay 23, 2024 | businesswire.comBicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual MeetingMay 23, 2024 | marketwatch.comBicycle Therapeutics Shares Rise 15% on $555M Expected from Private Placement DealMay 23, 2024 | msn.comBicycle Therapeutics gains as co announces $555M PIPE financingMay 23, 2024 | businesswire.comBicycle Therapeutics Announces $555 Million Private Placement Equity FinancingMay 20, 2024 | msn.comBicycle Kitchen’s grand opening kicks off in ScrantonMay 13, 2024 | msn.comBIKE MONTH: Bicycle Columbus to host coffee meetupMay 11, 2024 | msn.comPanama City Police Department gears up for Bicycle Rodeo eventMay 8, 2024 | bizjournals.comRoll Bicycle Co. closing its Bexley and Upper Arlington shops this monthMay 7, 2024 | finance.yahoo.comUpgrade: Analysts Just Made A Massive Increase To Their Bicycle Therapeutics plc (NASDAQ:BCYC) ForecastsMay 5, 2024 | msn.comJoplin Police Department hosts Bicycle Safety FairMay 4, 2024 | finance.yahoo.comBicycle Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | msn.comBicycle Safety Month brings safety tipsMay 3, 2024 | markets.businessinsider.comBicycle Therapeutics: Strong Q1 Performance and Promising Clinical Trials Drive Buy RatingMay 3, 2024 | yahoo.comBicycle Sundays on the Bronx River Parkway kicks off with 50th anniversary eventMay 2, 2024 | msn.comShenandoah Valley Bicycle Coalition celebrating National Bike MonthMay 2, 2024 | msn.comBCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | finance.yahoo.comBicycle Therapeutics PLC (BCYC) Q1 2024 Earnings: Narrowing Losses Amidst Robust R&D ProgressMay 2, 2024 | businesswire.comBicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial ResultsMay 2, 2024 | yahoo.comBombay Bicycle Club Announce 2024 Australian TourMay 1, 2024 | yahoo.comWhy the Bicycle Crunch Is One of the Best Core Moves for Cyclists—As Long As You Do It CorrectlyApril 26, 2024 | msn.comTrek Bicycle opens its first Reno store and showroomApril 25, 2024 | msn.comPlan for protected bike lanes along Oakland's Grand Avenue raising red flags for businessesApril 24, 2024 | businesswire.comBicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual MeetingSee More Headlines Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/14/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BCYC CUSIPN/A CIK1761612 Webwww.bicycletherapeutics.com Phone441223261503FaxN/AEmployees284Year FoundedN/APrice Target and Rating Average Stock Price Target$46.86 High Stock Price Target$65.00 Low Stock Price Target$32.00 Potential Upside/Downside+101.5%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-180,660,000.00 Net Margins-404.14% Pretax Margin-399.99% Return on Equity-49.35% Return on Assets-30.09% Debt Debt-to-Equity Ratio0.09 Current Ratio10.42 Quick Ratio10.42 Sales & Book Value Annual Sales$26.98 million Price / Sales36.87 Cash FlowN/A Price / Cash FlowN/A Book Value$12.35 per share Price / Book1.88Miscellaneous Outstanding Shares42,780,000Free Float39,143,000Market Cap$994.64 million OptionableOptionable Beta0.88 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Kevin Lee M.B.A. (Age 56)Ph.D., CEO & Executive Director Comp: $1.35MSir Gregory Paul Winter CBE (Age 73)FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder & Non-Executive Director Comp: $57.75kMs. Alethia Rene Young (Age 45)Chief Financial Officer Comp: $581.69kDr. Santiago Arroyo M.D. (Age 64)Ph.D., Chief Development Officer Comp: $916.98kDr. Christian HeinisScientific FounderMr. Alistair Milnes (Age 50)Chief Operating Officer Comp: $796.09kMr. Travis ThompsonSenior VP, Chief Accounting Officer & Principal Accounting OfficerDr. Michael Skynner B.sc. Ph.d. (Age 55)Ph.D., Chief Technology Officer Comp: $881.01kDr. Nicholas Keen Ph.D. (Age 56)Chief Scientific Officer Mr. Zafar QadirGeneral CounselMore ExecutivesKey CompetitorsImmunicNASDAQ:IMUXPerrigoNYSE:PRGOCrinetics PharmaceuticalsNASDAQ:CRNXAxsome TherapeuticsNASDAQ:AXSMCorcept TherapeuticsNASDAQ:CORTView All CompetitorsInsiders & InstitutionsComerica BankSold 3,080 shares on 5/17/2024Ownership: 0.184%Walleye Trading LLCSold 38,870 shares on 5/17/2024Ownership: 0.027%Kennedy Capital Management LLCSold 164,313 shares on 5/16/2024Ownership: 0.589%Bellevue Group AGSold 7,500 shares on 5/15/2024Ownership: 0.029%PEAK6 Investments LLCSold 6,000 shares on 5/15/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions BCYC Stock Analysis - Frequently Asked Questions Should I buy or sell Bicycle Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BCYC shares. View BCYC analyst ratings or view top-rated stocks. What is Bicycle Therapeutics' stock price target for 2024? 7 Wall Street analysts have issued 1-year price objectives for Bicycle Therapeutics' shares. Their BCYC share price targets range from $32.00 to $65.00. On average, they anticipate the company's share price to reach $46.86 in the next year. This suggests a possible upside of 101.0% from the stock's current price. View analysts price targets for BCYC or view top-rated stocks among Wall Street analysts. How have BCYC shares performed in 2024? Bicycle Therapeutics' stock was trading at $18.08 at the start of the year. Since then, BCYC shares have increased by 28.9% and is now trading at $23.31. View the best growth stocks for 2024 here. Are investors shorting Bicycle Therapeutics? Bicycle Therapeutics saw a decrease in short interest in May. As of May 31st, there was short interest totaling 2,620,000 shares, a decrease of 9.3% from the May 15th total of 2,890,000 shares. Based on an average daily volume of 379,300 shares, the short-interest ratio is currently 6.9 days. View Bicycle Therapeutics' Short Interest. When is Bicycle Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our BCYC earnings forecast. How were Bicycle Therapeutics' earnings last quarter? Bicycle Therapeutics plc (NASDAQ:BCYC) announced its quarterly earnings results on Thursday, May, 2nd. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.63. The business had revenue of $19.53 million for the quarter, compared to analyst estimates of $6.06 million. Bicycle Therapeutics had a negative net margin of 404.14% and a negative trailing twelve-month return on equity of 49.35%. The company's revenue was up 298.9% on a year-over-year basis. What ETFs hold Bicycle Therapeutics' stock? ETFs with the largest weight of Bicycle Therapeutics (NASDAQ:BCYC) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Harbor Health Care ETF (MEDI).Harbor Disruptive Innovation ETF (INNO). What other stocks do shareholders of Bicycle Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC). When did Bicycle Therapeutics IPO? Bicycle Therapeutics (BCYC) raised $64 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Bicycle Therapeutics' major shareholders? Bicycle Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baker BROS. Advisors LP (11.55%), First Light Asset Management LLC (2.79%), Westfield Capital Management Co. LP (3.46%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.94%), Price T Rowe Associates Inc. MD (0.94%) and Platinum Investment Management Ltd. (0.78%). Insiders that own company stock include Alistair Milnes, Kate Bingham, Kevin Lee, Lee Kalowski, Michael Charles Ferguso Hannay, Michael Skynner, Nicholas Keen, Nigel Crockett, Pierre Legault, Stephen B Alexander and Travis Alvin Thompson. View institutional ownership trends. How do I buy shares of Bicycle Therapeutics? Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCYC) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.